{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:47:05Z","timestamp":1789001225715,"version":"build-2803163510"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1038\/ajg.2015.20","type":"journal-article","created":{"date-parts":[[2015,3,3]],"date-time":"2015-03-03T08:11:58Z","timestamp":1425370318000},"page":"423-431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia"],"prefix":"10.14309","volume":"110","author":[{"given":"Kenichi","family":"Hosonuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Hashizume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Horiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Kakizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyasu","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210210","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1572-0241.2006.00634.x","article-title":"Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.","volume":"101","author":"Shi","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R2-15-20210210","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1111\/j.1572-0241.2006.00699.x","article-title":"Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients.","volume":"101","author":"ter Borg","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R3-15-20210210","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/gast.2002.31880","article-title":"Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients.","volume":"122","author":"Corpechot","year":"2002","journal-title":"Gastroenterology"},{"key":"R4-15-20210210","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep.20897","article-title":"Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis.","volume":"42","author":"Combes","year":"2005","journal-title":"Hepatology"},{"key":"R5-15-20210210","first-page":"227","article-title":"A European multicentre study group.","volume":"17","year":"1993","journal-title":"J Hepatol"},{"key":"R6-15-20210210","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1053\/jhep.2000.18663","article-title":"Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.","volume":"32","author":"Angulo","year":"2000","journal-title":"Hepatology"},{"key":"R7-15-20210210","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ajg.2013.51","article-title":"B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid.","volume":"108","author":"Myers","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R8-15-20210210","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0026-0495(93)90056-T","article-title":"The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities.","volume":"42","author":"Day","year":"1993","journal-title":"Metabolism"},{"key":"R9-15-20210210","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.hepres.2004.04.001","article-title":"Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis.","volume":"29","author":"Itakura","year":"2004","journal-title":"Hepatol Res"},{"key":"R10-15-20210210","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1386-6346(99)00033-9","article-title":"Beneficial effects of bezafibrate in ursodeoxycholic acid resistant pre-cirrhotic primary biliary cirrhosis.","volume":"16","author":"Iwasaki","year":"1999","journal-title":"Hepatol Res"},{"key":"R11-15-20210210","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","article-title":"The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study.","volume":"38","author":"Iwasaki","year":"2008","journal-title":"Hepatol Res"},{"key":"R12-15-20210210","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1440-1746.2011.06737.x","article-title":"Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid.","volume":"26","author":"Takeuchi","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"R14-15-20210210","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid.","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"R15-15-20210210","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis.","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R16-15-20210210","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"R17-15-20210210","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"R18-15-20210210","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group.","volume":"324","author":"Poupon","year":"1991","journal-title":"N Engl J Med"},{"key":"R19-15-20210210","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0025-6196(12)65350-6","article-title":"Application of the Mayo primary biliary cirrhosis survival model to Mayo liver transplant patients.","volume":"64","author":"Grambsch","year":"1989","journal-title":"Mayo Clin Proc"},{"key":"R20-15-20210210","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1365-2249.2000.01356.x","article-title":"Serum interferon-gamma-inducing factorIL-18 levels in primary biliary cirrhosis.","volume":"122","author":"Yamano","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"R21-15-20210210","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1001\/jama.285.15.2006","article-title":"CONSORT revisedimproving the reporting of randomized trials.","volume":"285","author":"Rennie","year":"2001","journal-title":"JAMA"},{"key":"R22-15-20210210","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.gastro.2005.05.009","article-title":"Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans.","volume":"129","author":"Marschall","year":"2005","journal-title":"Gastroenterology"},{"key":"R23-15-20210210","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1872-034X.2007.00297.x","article-title":"Ursodeoxycholic acid: mechanism of action and novel clinical applications.","volume":"38","author":"Ikegami","year":"2008","journal-title":"Hepatol Res"},{"key":"R24-15-20210210","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs: from orphan receptors to drug discovery.","volume":"43","author":"Willson","year":"2000","journal-title":"J Med Chem"},{"key":"R25-15-20210210","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1042\/bj20020981","article-title":"Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice.","volume":"369","author":"Kok","year":"2003","journal-title":"Biochem J"},{"key":"R26-15-20210210","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","article-title":"Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.","volume":"57","author":"Honda","year":"2013","journal-title":"Hepatology"},{"key":"R27-15-20210210","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cyto.2010.02.001","article-title":"TNFSF9 expression in primary biliary cirrhosis and its clinical significance.","volume":"50","author":"Xia","year":"2010","journal-title":"Cytokine"},{"key":"R28-15-20210210","first-page":"350","article-title":"Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.","volume":"104","author":"Dohmen","year":"2013","journal-title":"Fukuoka Igaku Zasshi"},{"key":"R29-15-20210210","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1751-2980.2012.00574.x","article-title":"Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy.","volume":"13","author":"Han","year":"2012","journal-title":"J Dig Dis"},{"key":"R30-15-20210210","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1874192401004010120","article-title":"Fenofibrate in primary biliary cirrhosis: a pilot study.","volume":"4","author":"Liberopoulos","year":"2010","journal-title":"Open Cardiovasc Med J"},{"key":"R31-15-20210210","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3748\/wjg.v10.i6.894","article-title":"Fenofibrate for patients with asymptomatic primary biliary cirrhosis.","volume":"10","author":"Dohmen","year":"2004","journal-title":"World J Gastroenterol"},{"key":"R32-15-20210210","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7326\/0003-4819-156-8-201204170-00401","article-title":"New fibrate use and acute renal outcomes in elderly adults: a population-based study.","volume":"156","author":"Zhao","year":"2012","journal-title":"Ann Intern Med"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg201520.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg201520","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg201520.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201503000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:21:22Z","timestamp":1786548082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201503000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2015.20","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}